The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRI | -85.49% | N/A | N/A | -100% |
| S&P | +12.26% | +86.71% | +13.3% | +61% |
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
No news articles found for Gri Bio.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 0.0% |
| Market Cap | $5.18M | 185.7% |
| Market Cap / Employee | $1.30M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$3.36M | -58.2% |
| EBITDA | -$3.36M | -58.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.06M | -14.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.03M | -64.3% |
| Short Term Debt | $0.05M | 14.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -219.61% | -52.0% |
| Return On Invested Capital | -962.44% | -20.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.31M | -2.0% |
| Operating Free Cash Flow | -$2.31M | -2.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.84 | 0.42 | 0.56 | 1.55 | 212.54% |
| Price to Tangible Book Value | 19.33 | 0.42 | 0.56 | 1.55 | 48.46% |
| Enterprise Value to EBITDA | -1.28 | 0.49 | 0.75 | -0.42 | -126.04% |
| Return on Equity | -382.6% | -468.0% | -248.9% | -397.8% | 41.70% |
| Total Debt | $0.12M | $0.11M | $0.10M | $0.08M | -35.88% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
